Skin Booster Delivery — What You Inject, and How It Gets Delivered

Three-Line Summary

• A skin booster result is not settled by its ingredient alone. The same product becomes a different treatment when depth, distribution and retention change, and the delivery method decides all three directly.
• Manual and device-assisted injection are not better and worse. They are tools with different jobs, because sculpting one point and covering a surface evenly are not the same skill.
• Delivery is decided by the physical properties of the product and its target depth. PN and hADM products aimed at the dermis, particulate products where micro-division works as a safeguard, and HA products that tolerate a slightly deeper plane each call for a different tool.

The Products Have Levelled Up. What Is Left Is Delivery

Rejuran, Juvelook, Re2O, CellREDM, GOURI, HILO WAVE, BELOTERO REVIVE — over the past few years the specifications of skin booster products have risen to a point where the gaps between them are no longer wide. So what separates results in clinic is moving away from the product name and towards where in the skin that product is left, and in what form.

When someone asks whether manual or device-assisted injection is better, we translate the question first. What change do you want, and for that change, how much product has to sit in which layer? Only once that is settled does the tool get settled. In practice, delivery acts on three things.

• Depth — did the product land in the target layer? The upper, mid and lower dermis and the subcutaneous fat compartment beneath them differ in tissue density and in how blood and lymph move through them. A difference of a few millimetres is not a small difference in the result.
• Distribution — did it spread evenly where evenness is needed, or precisely where precision is needed? A goal that lives on a surface, such as overall texture and pores, and a goal that lives at a point, such as a scar or a local depression, ask for the opposite distribution.
• Retention and loss — did it stay where it was meant to, without leaking and without clumping? What matters clinically is not the loss that runs out onto the skin but the loss that misses the target layer.

Once those three are settled, hand versus device stops being an argument and becomes a choice. Below we take each axis in turn.

To add one thing, when people say the same named treatment felt different from clinic to clinic, this is usually where it splits. The product name and the volume stay on the receipt, but which layer it went into, and in how many divisions, is not recorded anywhere. So the same 2cc may have been packed densely inside the dermis in one place and spread broadly through a deeper layer in another, which makes them two different treatments in practice. That is why a consultation here does not end at confirming the product name; we settle the target layer together as well.

One more thing in advance. This article is not trying to decide whether manual or device-assisted injection is superior. The two are physically good at different things, and the properties of the product and its target depth decide which one gets called. There is no conclusion waiting at the end, so please read it as the goal coming first and the tool following.

Depth — Hitting the Target Layer, and Two Kinds of Loss

Skin looks thin, but every layer responds differently. The same product behaves differently in the upper dermis than in the subcutaneous fat compartment: how fast it spreads, the route it takes through vessels and lymphatics, and how long it stays in the tissue all change. Given that most skin boosters are designed with the dermis as their stage, depth is not a side variable. It sits closer to a precondition of the treatment.

The Dermis Holds It; the Subcutis Lets It Go

The dermis is dense, so an injected product tends to be held where it lands. That is why small raised bumps appear right after treatment, and while the product sits there, cells have the time and the space to respond. The subcutaneous fat compartment is looser, with different vascular and lymphatic flow, so it can show a different distribution and absorption pattern from what you get when a depot is made in the dermis.

So if a product that has to stay in the dermis to work is laid down too deep, the product has certainly gone into the body, but effective exposure in the target layer can fall.

The Same Depth Is a Different Layer in a Different Area

Talking about depth in millimetres sounds precise, but the same number points to a different layer in different areas. Skin around the eyes and the mouth is thin, so a little extra travel passes straight through the dermis, while the cheek and forehead are relatively thick and the same depth may still sit in the mid dermis. That difference exists within a single face, and dermal thickness itself changes with age and skin condition.

So when we choose a delivery method, we look less at how many millimetres and more at which layer that depth corresponds to in this area. Needle angle, how far the skin is stretched and held, and injection speed all affect the layer actually reached. Device or hand, if that judgement is missing you end up with a treatment where the number is exact and the layer is off.

Loss That Leaks Out and Loss That Leaks In

When people hear the word loss, most picture fluid running out of the skin as the needle is withdrawn. It can certainly happen when injection pressure is high or speed is fast, and because you can see it, it bothers people. But this kind of loss is anticipated to some degree and built into the planned volume, so it rarely becomes a large variable.

What we watch more closely in clinical terms is the loss you cannot see. A product that should be working in the dermis is not left in the dermis but sent to another layer, and because nothing leaked on the surface and there was little pain, it can even look like a treatment that went well. That is also why the cause is hard to trace when the result turns out differently from what was expected.

Are the Bumps Marketing, or a Signal?

For a while the talk was about making good bumps, and more recently the talk is that the bumps do not matter and injecting deep makes no difference. Both claims are half right. The bumps cannot be the goal in themselves, but for a product that relies on a response inside the dermis, the bumps right after treatment can be read as a signal that the product reached its target layer.

Conversely, if hydration and glow are the goal, spreading smoothly without bumps suits the intention. If the skin looks unusually smooth immediately after a manual injection, it is worth considering once that the needle may have gone deep to avoid pain. Deeper layers offer less resistance, so the product goes in easily and it hurts less. A treatment that felt comfortable and a treatment that landed precisely in the target layer do not always point the same way.

Manual Injection — Sculpting One Point at a Time

In manual injection the operator feels the resistance at the needle tip and places the product one stitch at a time. Its greatest strength is being able to change judgement as the situation changes.

• Depth control — within one face, the eye and mouth areas are thin and the cheek is thick. Manual injection can change the depth the moment the area changes.
• Point control — this spot is a scar so it takes a little more, that spot has thin skin so it must not clump. Local optimisation of that kind is possible.
• Volume per point — the amount per stitch can be divided very finely, and where it helps, enough can be placed in one spot to drive a larger response.

The limits are just as clear. A human hand cannot repeat the same movement hundreds of times identically, so when the whole face needs an even density, variation creeps in more easily than with a device. Working stitch by stitch takes longer, and pushing a large volume into limited dermal space increases pain. Bruising is also relatively more common than with device-assisted injection.

Pain Is Not the Price of Depth. It Is Something to Manage

Pain in manual injection does not rise simply because of the number of punctures. Pushing a set volume into dense dermal space in a short time stretches the tissue and creates pressure, and that pressure itself is felt as pain. So if you change depth to reduce pain you miss the target layer, and if you hold the target layer the pain remains. That is the structure of the problem.

In that situation, adjusting other variables rather than conceding depth is the better way to protect the goal. The anaesthesia can be changed, the volume and speed at each point can be divided, and the delivery method can be switched by area. Reducing pain and holding the target layer are not an either-or. They are two items that can be designed separately.

So there are specific situations where the strength of manual injection really comes through. It is when placing a generous amount in one spot is meaningful, and doing so carries little burden in the way of clumping or long-lasting bumps. If the plan is only to place small amounts evenly, the reason to do it by hand shrinks. This criterion comes back later when we talk about individual products.

Device-Assisted Injection — Covering a Surface Evenly

Device-assisted injection divides the product automatically and delivers it at a set interval and depth. It is usually explained as being even, but what matters more in clinical terms is the safety margin that evenness creates.

Why Micro-Division Works as a Safeguard

With particulate collagen-stimulating products, the thing to watch most closely is clumping from over-injection. Clumping often starts not with the total volume but with the concentration at one point. By hand, roughly 0.01-0.02cc tends to go in at a time, while an automated injector can split that into far smaller units and lay them down at a set interval. The same total volume goes in, but the concentration at any one point is lower, so the room for clumping is structurally reduced. The actual division unit varies with the device and the settings.

This difference is less a matter of evenness than a difference in how risk is managed. With particulate products, then, device-assisted injection is not the easy option. It becomes part of the design.

What an Even Interval Produces

The meaning of evenness is worth pinning down as well. Concerns that are perceived as a surface, such as texture and pores, are felt not through whether one point improved but through whether the whole area changed to a similar degree. If some spots received plenty and others were left empty, the same average volume can still leave a patchy impression.

The fixed interval of a device reduces that variation. But even does not mean it takes care of itself. Which depth to set, and where to change the setting by area, is still the operator's call, and repeating the wrong depth evenly leaves the same error spread neatly across the whole face. That is why the first setting weighs heavily in device-assisted injection too.

What Device-Assisted Injection Does Less Well

Flexibility, in exchange, does not match the hand. Where the surface curves sharply or skin thickness changes abruptly, depth is hard to adjust on the spot, and delicate areas such as just under the eye or beside the nose end up needing a human hand. The limited ability to add extra volume in one specific area has to be weighed in as well.

In short, manual and device-assisted injection are good at different things. Going to a conclusion that one of them is the better method means losing sight of what the product in front of you actually needs.

The Properties of the Product Decide the Delivery

This is where the real consultation begins. Products all called skin boosters have quite different characters, and the delivery strategy has to change with that character.

Rejuran (PN) — It Has to Be Left in the Dermis

The main component of Rejuran Healer, PN (polynucleotide), works in the direction of acting on regenerative signalling in cells within the dermis. Off the target layer the expected response can weaken, and the mechanical stimulus created as it settles into dermal tissue acts as a separate benefit. So with Rejuran, designing a depot in the precise layer comes before going comfortably deep. It is the representative product where manual injection takes the lead.

Juvelook — Dividing Evenly Is the Safety Measure

The Juvelook family induces collagen production through stimulation. With this family, injecting without clumping comes before amplifying the effect. Concentrating at one point raises the risk of nodules, so dividing finely and laying the product down at a set interval by device becomes the natural choice. At ABLE Dermatology too, the Juvelook family runs on device injection as the default. For reference, Juvelook Volume, which targets volume, is a PDLLA collagen booster with a different target layer and design from a dermal skin booster.

Re2O and CellREDM — Placing hADM (ECM) in the Dermis

Re2O and CellREDM are human acellular dermal matrix, the hADM (ECM) family. Rather than stimulating collagen production, the idea is closer to restocking material directly where the dermal extracellular matrix has emptied out. So the main stage for this family is likewise the dermis, and what depth the product was placed at, and how, weighs heavily on the result. Where dermal density and texture are the goal, intradermal injection is the baseline, and where a wide surface has to be filled evenly, an even-delivery method is used alongside it.

GOURI — Laying a Mesh Beneath the Dermis

GOURI is liquid PCL. It is thin as water and spreads readily, but the dermis above is dense, so it does not diffuse far in that direction and instead settles broadly in the comparatively loose subdermal plane. Since the goal is not to fill the dermis but to build a mesh that supports the tissue from beneath it, GOURI is centred on cannula delivery. Device-assisted or needle-free injection is added as a secondary route when more weight is placed on surface texture.

HILO WAVE and BELOTERO REVIVE — HA That Holds a Slightly Deeper Plane

HILO WAVE is a Dual-HA carrying both high and low molecular weight fractions, and BELOTERO REVIVE is an HA booster combining highly concentrated hyaluronic acid with glycerol. This family draws water strongly and its particles are bound to one another, so the change you are looking for can still be obtained when it is laid broadly in the plane just beneath the dermis. In fact, injecting it into the dermis the way Rejuran is injected can leave bumps that last, which pushes the choice slightly deeper, and once you go that deep the practical difference from a cannula is not large. Deeper planes do call for attention to vessels and bruising.

The table is a summary of the criteria, and even with the same product the method changes with the area and the goal. Opinions on technique can differ from operator to operator.

One more addition. Even within the same product, a split in formulation changes the delivery. With Rejuran alone, Healer, HB+ and the eye formulation are used differently depending on the situation, and in thin-skinned areas such as under the eye the room in the available layer is narrow, so volume per point and depth are set far more conservatively. The same product name does not mean the same technique, so please read it as the conditions of the area treated in that session resetting the method.

Cannula — The Route for Going Deep and Wide

A cannula is a long tube with a blunt tip. Instead of piercing through tissue like a needle, it pushes between tissue planes, so bruising and pain tend to be lower and one entry can cover a wide area. Because it is comfortable to receive, we are often asked why every skin booster is not simply done with a cannula.

But a cannula is a tool suited to handling a deep plane over a wide area. So the products that suit it are the ones designed from the outset to settle beneath the dermis. GOURI, as above, is the representative case, and cross-linked HA products sit close to it.

Conversely, laying a product that has to stay inside the dermis to work, such as Rejuran or the hADM family, deep and wide with a cannula can skip the very layer where the response is needed and spread the product elsewhere. The claim that a cannula gives the same outcome holds for some products, but it does not transfer as it stands to products that have to land precisely inside the dermis.

One more point. A cannula may be gentler than a needle, but vessels run through the deeper planes. Handled roughly it can push or injure a vessel, so careful technique is needed even when the plan is to go deep.

Where Needle-Free Delivery Fits — Synerjet

The needle-free delivery device used at ABLE Dermatology is Synerjet. It drives the product into the skin with pressure rather than a needle puncture, so it leaves no needle marks, distributes relatively evenly through the dermis, and tends to be lighter on pain and recovery. Several formulations can be run on the same device, including Rejuran, Juvelook, Re2O, GOURI and microbotox, treatment takes roughly 20-30 minutes, and depending on the product a series of 3-5 sessions at 3-4 week intervals is often recommended.

Contact Injection and Spraying From a Distance Are Not the Same Thing

Two things often get mixed together when needle-free injectors come up. One is holding the device against the skin and driving the product into the dermis with pressure. The other is holding it at a distance and misting the surface. The first genuinely counts as injection, placing product inside the dermis, while the second reaches only a shallow depth on intact skin, so meaningful entry into the dermis is often hard to expect. It can help with surface hydration, but taken on its own as the main treatment the difference people feel varies widely.

It Changes Once the Channels Are Made First

So the spray-at-a-distance mode does its work after micro-channels already exist. Run a treatment that creates fine channels in the skin first, such as microneedle RF like Potenza or fractional CO2, and then use it as a secondary route to carry the product in, and delivery efficiency comes back. Following a Potenza or Pico Fraxel session in the pore programme at ABLE Dermatology with Synerjet to carry product in works on the same logic.

The place for needle-free delivery is clear. It is when needle marks or bruising have to be avoided, when a wide area has to be treated evenly, and when product needs to follow a treatment that has made channels. Where a generous amount has to be concentrated on one local scar, manual injection is still needed.

Because of the impression the word needle-free gives, it is sometimes mistaken for a weak form of delivery. What actually separates the outcomes is not the presence of a needle but whether the conditions for the product to reach the dermis were created. Placing product in the dermis by contact injection, and carrying product in after channels have been made, are both cases where those conditions are met. Laying product on the surface without them gives a different range of expectations even on the same device.

Afterwards there are no needle marks, and mild redness tends to settle within a few hours, so makeup is often possible the same day or the next. Depending on the product used, mild bruising or a nodular feel can continue for a few days, so it is hard to say there is no recovery process simply because it is needle-free. Conditions that make treatment unsuitable, such as pregnancy or breastfeeding, or active inflammation at the treatment site, apply the same as for the product itself.

Combination and Interval — Designing a Series, Not a Session

In practice it is rare to pick hand or device as a single answer. Laying an even base at the same depth across the whole face with a device to settle inner dryness and texture, then reinforcing the areas that need detail by hand, stitch by stitch, is the more natural combination. Cannula and needle-free delivery join in here as the goal requires.

Designing It in Stacked Depths

The Layered Booster at ABLE Dermatology is an example of this approach. GOURI is distributed evenly from the deep to the mid dermis, Re2O is aligned in the mid dermis, and microbotox is distributed finely in the superficial layer, stacking depths in order within a single session. Because each component acts in a different layer and over a different time course, separating the layers serves each role better than concentrating everything in one. Warming the dermis with the Density Alpha tip and then delivering GOURI with Synerjet, as in Synergy RF, comes from the same idea.

The Order Has Reasons Too

When several layers are treated in one session, we generally settle the deep layers first and come up to the shallow ones. Filling the shallow layer first brings swelling and bumps over the top of it, which makes the boundary of the layer below hard to judge, and passing back through an area already injected can disturb the distribution just built. The order is less a matter of preference than a procedure for leaving yourself grounds to judge at the next step.

For the same reason, we control how many products overlap in one session. The strength of stacking by layer lies in letting each component work in its own place, so if too much goes in at once the boundaries between layers blur and the response becomes harder to read. Watching the response and reinforcing at the next session is lighter than going for the maximum from the start.

Why the Interval Differs by Product

Evenness is not only a question within a single session. The interval between sessions affects distribution too. If the next session overlaps while the product from the previous one has not yet been cleared, more than intended can accumulate in one layer, and if the gap is stretched too far the cumulative effect does not build. That is why criteria differ by product, with 3-5 sessions at 4-week intervals for Rejuran and the hADM family, and 3-5 sessions at 3-6 month intervals for HA products such as HILO WAVE or BELOTERO REVIVE.

The 24 Hours After Treatment Are the Last Variable in Distribution

Right after injection the product is still settling into place. Pressing hard or rubbing can disturb a distribution built with care, so it is better to avoid firm pressure and massage over the injected area for 24 hours. Sauna and vigorous exercise on the day of treatment, and alcohol for a week, are activities that raise blood flow sharply and affect bruising and swelling. Depending on the product, mild bruising or a nodular feel can continue for around 5-7 days, and this is usually a course that resolves on its own. If symptoms persist or worsen, it is better to have them checked where the treatment was done.

In the end what matters is not which device was used but how depth and distribution were designed around the goal. Manual and device-assisted injection are different tools for carrying out that design, and results vary between individuals.

From Consultation to Treatment

A board-certified dermatologist examines you directly, identifies the layer behind the problem, sets the device and parameters, and then carries out the treatment personally. There is no consultant here to recommend procedures.

Sessions, intervals, maintenance timing and cost are agreed together before the first treatment.